The journal Nature reports today that researchers may have found a way to correct the chromosome defect that causes Down syndrome, though it will be years before it could possibly be tried in humans.
Down syndrome affects an estimated 6 million people worldwide; it tends to impair physical growth and intelligence, and can cause serious medical problems from heart defects to early dementia.
The syndrome is caused by an extra copy of Chromosome 21, and in today’s Nature paper, researchers at the University of Massachusetts Medical School describe a way to “silence” that extra chromosome, meaning it’s still there but its genes don’t get “turned on,” they don’t function and cause problems.
They call this “chromosome therapy.” You’ve heard of “gene therapy” — the still somewhat futuristic idea that if you have a disease that’s caused by a defect in a single gene, we send in a virus engineered to carry a sort of “fix-it” gene to cure you.
Chromsome therapy means that if your problem is a whole chromosome, containing hundreds of genes — as it is in Down syndrome — you could also use genetic engineering to fix that.
Jeanne Lawrence, the lead researcher on the Nature paper, says this is “the first time a single gene or any means has been used to silence a chromosome for the purposes of correcting a chromosomal abnormality (a problem which is surprisingly common).”
“Unlike gene therapy for single gene defects, any strategy for gene therapy to address a whole chromosome disorder has been outside the realm of consideration,” she said. “Now, this work makes ‘chromosome therapy’ conceivable, but still a very long-term prospect. In the short-term, this new strategy will accelerate Down syndrome research in multiple ways, including helping to identify drugs that mimic the effects of silencing the extra chromosome in human cells.”
So how do you silence a whole chromosome? Dr. Lawrence and her team found a way to reuse something that already occurs in us naturally: a gene called XIST — pronounced “exist.” In female mammals, it already functions to ratchet down one of our X chromosomes.
Dr. Lawrence and her team got what’s called a “high risk high impact” federal grant — translation: a real long shot but really great if it works — to try to use XIST, that gene that affects the X chromosome, to try to silence chromosome 21, the problem in Down Syndrome.
And it worked. Not in full human bodies, but in human cells, and they have begun work to test this idea in mouse models of Down syndrome.
Of course, it’s always a long and uncertain road from mice to humans, but Dr. Lawrence says that in the short term, this ability to silence that extra chromosome is an important scientific tool to help figure out what exactly goes wrong in the cells of different organs, and to look for drugs that could treat it.
And eventually, in some years, it could lead to methods to just turn off that extra chromosome in certain cells or regions of the body in children born with Down syndrome — or even before they’re born.
Which leads us to the usual discussion about Down syndrome: as the focus of prenatal testing. The tests for Down syndrome have been getting easier and earlier in pregnancy — could these new findings add one more wrinkle to the decisions that face parents-to-be?
In a word, yes. I spoke with Dr. Brian Skotko, the co-director of the Down syndrome program at Massachusetts General Hospital, and he says that expectant parents often ask him whether there’s a cure for Down Syndrome — and that this new paper is going to change his answer.
“Right now,” he said, “there is no treatment for Down syndrome per se — we can help with the effects of Down syndrome, we can treat the medical conditions — but I can now insert into my conversation: ‘Research is being done and there is promise that one day they might be able to figure out how to turn off most of the effects of that extra chromosome.’”
To which I responded, “Oh, great, so those incredibly difficult prenatal Down syndrome decisions are going to get even harder for now.”
But there’s no question, this is a real advance in Down syndrome research. Dr. Skotko says the main promise of the Nature paper is clearly a long-term prospect, but “that light was never even flickering at the end of our tunnel until this paper was published. So for the first time, the Down Syndrome movement has long-term possibilities which we never really had until papers like this started to come out.”
Readers? Thoughts? It’s completely imaginary, but I found myself wondering: What if you had a child with Down syndrome, and a treatment came along that would make the child smarter but less happy. What would you do?
For more scientific details, here’s the University of Massachusetts press release:
UMASS MEDICAL SCHOOL SCIENTISTS SHOW PROOF-OF-PRINCIPAL FOR SILENCING EXTRA CHROMOSOME RESPONSIBLE FOR DOWN SYNDROME
Successful silencing of one chromosome 21 advances translational research and surmounts the first major obstacle to “chromosome therapy” in patient-derived stem cells in culture.
WORCESTER, MA – Scientists at the University of Massachusetts Medical School are the first to establish that a naturally occurring X chromosome “off switch” can be rerouted to neutralize the extra chromosome responsible for trisomy 21, also known as Down syndrome, a genetic disorder characterized by cognitive impairment.
The discovery provides the first evidence that the underlying genetic defect responsible for Down syndrome can be suppressed in cells in culture (in vitro). This paves the way for researchers to study the cell pathologies and identify genome-wide pathways implicated in the disorder, a goal that has so far proven elusive. Doing so will improve scientist’s understanding of the basic biology underlying Down syndrome and may one day help establish potential therapeutic targets for future therapies. Details of the study by Jiang et al. were published online in Nature.
“The last decade has seen great advances in efforts to correct single-gene disorders, beginning with cells in vitro and in several cases advancing to in vivo and clinical trials,” said lead author Jeanne B. Lawrence, PhD, professor of cell & developmental biology at the University of Massachusetts Medical School. “By contrast, genetic correction of hundreds of genes across an entire extra chromosome has remained outside the realm of possibility. Our hope is that for individuals living with Down syndrome, this proof-of-principal opens up multiple exciting new avenues for studying the disorder now, and brings into the realm of consideration research on the concept of “chromosome therapy’ in the future.”
Humans are born with 23 pairs of chromosomes, including two sex chromosomes, for a total of 46 in each cell. People with Down syndrome are born with three (rather than two) copies of chromosome 21, and this “trisomy 21” causes cognitive disability, early-onset Alzheimer’s disease; and a greater risk of childhood leukemia, heart defects and immune and endocrine system dysfunction. Unlike genetic disorders caused by a single gene, genetic correction of a whole chromosome in trisomic cells has been beyond the realm of possibility, even in cultured cells.
Harnessing the power of the RNA gene called XIST, which is normally responsible for “turning off” one of the two X chromosomes found in female mammals, UMass Medical School scientists have shown that the extra copy of chromosomes 21 responsible for Down syndrome can be silenced in the laboratory using patient-derived stem cells.
The natural function of the XIST gene, located on the X chromosome, is to effectively silence one of the two X chromosomes in female cells, making expression of X-linked genes similar to that of men, who have just one X chromosome. The large XIST RNA is produced early in development from one of the female’s two X chromosomes, and this unique RNA then “paints” the X chromosome and modifies its structure so that its DNA can’t be expressed to produce proteins and other components. This effectively renders most of the genes on the extra chromosome inactive.
Motivated by the idea that this effect might be replicated in an extra chromosome 21 in trisomic cells, Lawrence and colleagues Lisa Hall PhD, assistant professor of cell and developmental biology at UMMS and Jun Jiang, PhD, instructor of cell and developmental biology at UMMS, began a research project to insert the XIST gene into one chromosome 21 – supported by NIH funding for high-risk, high-impact work. They worked to do this in induced pluripotent stem cells derived from fibroblast cells donated by a Down syndrome patient because stem cells have the special capacity to form different cell types of the body. Their work showed that the large XIST gene could be inserted at a specified location in the chromosome using zinc finger nuclease (ZFN) technology, a key tool provided by collaborators at Sangamo BioSciences, Inc., a biotechnology company based in Richmond, California. Furthermore, RNA from the inserted XIST gene effectively repressed genes across the extra chromosome, returning gene expression levels to near normal levels and effectively silencing the chromosome.
This finding opens multiple new avenues for translational scientists to study Down syndrome in ways not previously possible. Determining the underlying cell pathologies and gene pathways responsible for the syndrome has previously proven difficult, because of the complexity of the disorder and the normal genetic and epigenetic variation between people and cells. For example, some prior studies suggested that cell proliferation in Down syndrome patients may be impaired, but differences between people and cell lines made it difficult to conclude this definitively. By controlling expression of the XIST gene, Lawrence and colleagues were able to compare otherwise identical cultures of the Down syndrome cells, with and without expression of the extra chromosome. What they showed is that the Down syndrome cells have defects in cell proliferation and in neural cell differentiation, both of which are reversed by silencing one chromosome 21 by XIST.
“This highlights the potential of this new experimental model to study a host of different questions in different human cell-types, and in Down syndrome mouse models” said Lawrence. “We now have a powerful tool for identifying and studying the cellular pathologies and pathways impacted directly due to over-expression of chromosome 21.”
“Dr. Lawrence has harnessed the power of a natural process to target abnormal gene expression in cells that have an aberrant number of chromosomes,” said Anthony Carter, PhD, of the National Institutes of Health’s National Institute of General Medical Sciences, which partly supported the study. “Her work provides a new tool that could yield novel insights into how genes are silenced on a chromosomal scale, and into the pathological processes associated with chromosome disorders such as Down syndrome.”
New discoveries made using this approach could one day identify new therapeutics for chromosome disorders like Down syndrome. “In the short term the correction of Down syndrome cells in culture accelerates the study of cell pathology and translational research into therapeutics, but also for the longer-term, potential development of “chromosome therapies”, which utilizes epigenetic strategies to regulate chromosomes, is now at least conceivable. Since therapeutic strategies for common chromosomal abnormalities like Down syndrome have received too little attention for too long, for the sake of millions of patients and their families across the US and the world, we ought to try. ” said Lawrence.
Lawrence and colleagues will now use this technology to test whether “chromosome therapy” can correct the pathologies seen in mouse models of Down syndrome.